

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

## Levodopa-carbidopa intestinal gel infusion and weight loss in Parkinson's disease

### **This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1678671> since 2018-10-25T09:53:03Z

*Published version:*

DOI:10.1111/ene.13844

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

DR. MAURIZIO ZIBETTI (Orcid ID : 0000-0002-2939-343X)

DR. ALBERTO ROMAGNOLO (Orcid ID : 0000-0002-1312-1843)

Article type : Original Article

## **Levodopa-carbidopa intestinal gel infusion and weight loss in Parkinson's disease**

Margherita Fabbri<sup>1,2</sup>, Maurizio Zibetti<sup>2</sup>, Laura Beccaria<sup>2</sup>, Aristide Merola,<sup>3</sup> Alberto Romagnolo<sup>2</sup>, Elisa Montanaro<sup>2</sup>, Joaquim J Ferreira<sup>1,4</sup>, Sara Palermo<sup>5</sup>, Leonardo Lopiano<sup>2</sup>

<sup>1</sup>*Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Portugal*

<sup>2</sup>*Department of Neuroscience "Rita Levi Montalcini", University of Torino, Via Cherasco 15, 10124, Turin, Italy*

<sup>3</sup>*Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA*

<sup>4</sup>*Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal*

<sup>5</sup>*Department of Psychology, University of Turin, Via Verdi 10, 10124, Turin, Italy*

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/ene.13844

This article is protected by copyright. All rights reserved.

**Corresponding author:** Maurizio Zibetti

Department of Neuroscience "Rita Levi Montalcini", University of Torino, Via Cherasco 15,  
10124, Turin, Italy

Tel: 011/6709366

Fax: 011/6709351

E-mail: maurizio.zibetti@gmail.com

**Running title:** levodopa/carbidopa intestinal gel and weight loss

**Key words:** Parkinson's Disease, levodopa/carbidopa intestinal gel, weight loss, disease progression, malnutrition;

## **Abstract**

**Introduction:** Weight loss (WL) is a frequent yet under-recognized complication of levodopa/carbidopa intestinal gel (LCIG) infusion, as well as a milestone of Parkinson disease (PD) disability progression. The complex association between weight loss, poor nutritional status, motor complications, and PD progression, however, remains unclear.

**Methods:** Consecutively consenting PD patients treated with LCIG (n= 44; PD duration= 18.3±6.5 years) were enrolled in an open-label observational study assessing the extent of WL occurring during LCIG treatment. As secondary aims, we correlated the nutritional status, as detected by the mini nutritional assessment (MNA), with the severity of motor symptoms (Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-

UPDRS) section-III), motor complications (UPDRS section-IV), activities of daily living (Schwab & England scale), cognitive impairment (Mini Mental State Examination - MMSE), depression (Beck Depression Inventory - BDI), difficulties in feeding (Edinburgh feeding evaluation in dementia questionnaire - EdFED-Q), and levodopa equivalent daily dose (LEDD).

**Results:** There was an average WL of  $9.9 \pm 10.5\%$  ( $7.6 \pm 7.1$  kg) over an LCIG treatment period of  $51.6 \pm 28.5$  months. The extent of WL correlated with the percentage of waking day spent with dyskinesia ( $p < 0.05$ ). The nutritional status correlated with motor symptoms severity ( $p < 0.01$ ), dysphagia ( $p < 0.01$ ), and LEDD ( $p < 0.01$ ).

**Conclusion:** WL may occur in PD patients undergoing LCIG in correlation with the percentage of the waking day spent with dyskinesia. Regardless of the extent of WL, the nutritional status correlated with higher LEDD, as well as with indexes of disease progression, such as motor symptoms severity and dysphagia.

## Introduction

Patients with Parkinson's disease (PD) are consistently reported to be underweight compared to healthy subjects [1]. Weight loss (WL) may begin several years prior to the clinical diagnosis [2] in association with various factors, including PD-associated hyposmia, dysphagia, difficulties in self-feeding, intestinal hypomotility, depression, cognitive impairment, anorexia, and nausea, as well as with increased energy expenditure due to rigidity, tremor, and levodopa-induced dyskinesia [1, 3].

Multiple evidences suggest a key role for WL as a biomarker of disease progression in PD and other neurodegenerative disorders [4, 5]. In fact, the body mass index (BMI), which is calculated as weight in kilograms divided by height in square meters, is a strong predictor of

Accepted Article  
survival in PD [4, 5]. Moreover, WL correlates with several non-motor complications directly associated with poor PD functional status, such as cognitive impairment and orthostatic hypotension [3].

In previous studies, we found that PD patients treated with levodopa/carbidopa intestinal gel (LCIG) infusion may be particularly susceptible to WL. Causative factors for this phenomenon, however, remain partially unclear and are likely related to a multifactorial interplay between intestinal malabsorption, global deterioration of the overall clinical conditions, and a possible effect of dopaminergic medications on the appetite [6, 7].

The main aim of this study is to evaluate prevalence and severity of WL occurring during LCIG treatment and to analyze the association between the nutritional status of PD patients undergoing LCIG and motor and non-motor indexes of PD disability progression.

### **Patients and Methods**

Inclusion criteria were idiopathic PD, as per the UK Brain Bank criteria [8]; treatment with LCIG for at least 6 months; and availability of weight measurement before starting LCIG.

Exclusion criteria were signs or symptoms suggestive of atypical parkinsonism; bariatric surgery; poor general health; and medical conditions potentially associated with pathological WL such as gastroenteric disorders, malignancies, thyroid dysfunction, etc.

As primary endpoints, we measured changes in the body weight and BMI between T0 (about one week, range: 1-7 days, before starting LCIG) and T1 (last outpatient visit on LCIG therapy). Secondary endpoints included the Mini Nutritional Assessment (MNA), an 18-item questionnaire based on anthropometric measurements, eating habits, psychological, and functional aspects associated with nutrition specifically validated for nutritional assessment of community and institutionalized elderly patients [9]; the Edinburgh Feeding Evaluation in

Dementia Questionnaire (EdFED-Q), a 11-items clinical questionnaire assessing behaviours of feeding difficulty (e.g. refusing to eat, turning head away while being fed, spitting out food), nursing intervention (e.g. supervision, physical help) and patient passivity during meals (e.g. spillage, leftover) [10]; the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part-II, part-III, and UPDRS part-IV; the Mini Mental State Examination (MMSE); the Beck Depression Inventory Scale (BDI); the Schwab and England (SE) scale of activities of daily living (ADL); and the levodopa equivalent daily dose (LEDD), calculated as per a validated conversion table [11] and expressed as LEDD/Kg. Items 32 and 33 of the UPDRS were used to assess the duration and severity of dyskinesia, the MDS-UPDRS item 2.3 to rate the severity of dysphagia. Validated conversion tables were applied to convert data from the UPDRS part-II and -III to the MDS-UPDRS part-II and -III, when needed [12].

All patients were evaluated for peripheral neuropathy (PNP), defined as symmetric alteration of action potential amplitudes or velocities in at least two motor or sensory nerves at the nerve conduction studies (NCS) [13]. PNP were classified as “subclinical” when presenting with electrophysiological alteration not accompanied by clinical symptoms.

The ethical committee approval was obtained (CS2/535; protocol number 0006409) and patients provided written informed consent.

### **Statistical analysis**

Continuous variables were described as mean  $\pm$  standard deviation. Categorical variables as frequencies or percentage. Changes in body weight between T0 and T1 were calculated as per the following formula:  $(\Delta \text{ kg [T0-T1]}/\text{body weight at T0}) * 100$ ). Correlations analyses were carried out using a two-step approach. First, a Pearson's rank correlation coefficient was

applied. Then, data showing significant correlation at the univariate analysis were selected as independent variables in a multiple linear regression model adjusting for PD duration and LCIG treatment duration. Two-tailed p-values lower than 0.05 were considered statistically significant. Analyses were carried out using SPSS 24.0 (SPSS, Chicago, IL).

## Results

We enrolled 44 patients, corresponding to 82% of the entire population (n = 54) in active treatment with LCIG at our center. Exclusions were due to poor general health (n = 3 cases), LCIG duration shorter than 6 months (n = 3 cases), lack of data at T0 (n = 2 cases), detainment in prison (n = 1 case), and diagnostic revision into multiple system atrophy (n = 1 case). The duration of LCIG therapy was  $51.6 \pm 28.5$  months (range: 10-120 months).

Clinical, demographic, and nutritional data are detailed in Table 1.

There was an average WL of  $9.9 \pm 10.5\%$  between T0 and T1, corresponding to a weight change greater than 10 Kg in 12 patients (27%); ranging from 6 to 10 Kg in 12 patients (27%); and from 2 to 5 Kg in 6 patients (13%). No significant weight changes were observed in the remaining 16 patients.

At T1, 19 patients (43%) had a BMI  $< 22 \text{ kg/m}^2$ , which is considered the threshold for undernutrition in elderly population; 9 (21%) met the criteria for malnutrition (MNA score  $< 17$ ) and 6 (14%) required nocturnal enteral feeding to supplement their dietary intake.

Motor complications (UPDRS-IV) improved due to a reduction in the severity of wearing-off, while no significant changes were observed in the duration and severity of dyskinesia (Table 1). The prevalence of PNP increased between T0 and T1, with 8 cases of subclinical PNP becoming “symptomatic”, and 8 cases with normal neurophysiological examination

developing a subclinical PNP ( $p=0.001$ ; Table 1). The dose of dopaminergic therapies significantly increased between T0 and T1 ( $p=0.002$ ).

A direct correlation was observed between the extent of WL and the percentage of waking day spent with dyskinesia ( $\beta=0.381$ ;  $p=0.006$ ), and between MNA and the following variables: HY score ( $\beta=0.287$ ;  $p=0.012$ ); dysphagia severity ( $\beta=0.227$ ;  $p=0.007$ ); MDS-UPDRS-III total score at T1 ( $\beta=0.320$ ;  $p=0.009$ ); EdFED-Q total score ( $\beta=0.320$ ;  $p=0.008$ ); and LEDD/Kg ( $\beta=0.290$ ;  $p=0.002$ ) (Table 2). Patients developing clinical or subclinical PNP between T0 and T1 showed a worse nutritional status ( $p=0.005$ ) though not a greater WL.

## Discussion

The complex relationship between food intake and weight changes in PD remains unclear. Regardless of food intake, PD patients have lower BMI than healthy subjects [14]. Moreover, a decrease in the BMI correlates with a more aggressive pattern of motor symptoms progression [4], suggesting that PD-associated body weight changes are not necessarily due to reduced caloric intake but may rather correlate with underlying disease mechanisms.

The relationship between WL and PD is even more complex in patients undergoing LCIG. In a previous study, we found that 17% of patients treated with LCIG developed a WL greater than 10kg over a 2-year observational period [6]. Significant changes in body weight were also reported by other authors. Sensi and colleagues described an average WL of 14.7% (10.8 kg) over a 6-year follow-up in patients treated with LCIG, Antonini and colleagues reported a WL of 6.7% over 24 months, and Buongiorno and colleagues a WL of 7% over 22 months [6, 15-17].



To the best of our knowledge, this is the first study specifically investigating factors associated with body weight changes in PD patients with long-term exposure to LCIG. We found that 68% of patients developed a mild to severe WL after  $4.5 \pm 2.3$  years, 27% had a WL greater than 10kg, and 21% met the criteria for malnutrition. After adjusting for LCIG duration, the duration of dyskinesia was the only factor associated with WL, while severity of motor symptoms, dysphagia, and dose of dopaminergic medications correlated with the nutritional status.

Overall, we observed a prevalence and severity of WL that was relatively higher compared to other studies [7, 16, 17], possibly reflecting the greater level of attention devoted to body weight, an outcome frequently neglected or relegated to the role of ancillary measure.

However, we cannot exclude the influence of factors such as the long follow-up duration and the inclusion of patients in an advanced stage of disease. Interestingly, we did not find any correlations between WL and disease severity, expressed as motor disability (i.e. SE, HY, MDS-UPDRS-III or  $\Delta$ MDS-UPDRS-III), cognitive or neuropsychological impairment (MMSE, BDI and MDS-UPDRS items 1.1-1.5), and peripheral nervous system involvement.

Instead, we observed an association between WL and the percentage of the waking day spent with dyskinesia. A post-hoc analysis of our data suggests that an adjustment in the dose of dopaminergic therapies for body weight changes might be required to minimize dyskinesia due to a relative LEDD/kg increase, which may ultimately worsen the severity of peak-dose dyskinesia with increased energy expenditure and consequent WL [3, 18]. Also, the relatively low score observed at the EdFED-Q indicates that WL was primarily due to increased energy expenditure rather than feeding difficulties.

Since WL not necessarily implies malnutrition [19], we used the MNA to investigate factors primarily contributing to the nutritional status. Overall, we observed that 43% of patients were at risk of malnutrition and 21% were undernourished. These data are in line with the

published literature, which reports a 0 to 24% prevalence of malnutrition in PD, depending on the study methodology and definition criteria [20]. Interestingly, we found that dyskinesia alone is not a determinant of nutritional status, while disease severity (expressed as HY staging and MDS-UPDRS-III score), dysphagia, feeding difficulties (expressed as EdFED-Q score), dosage of dopaminergic therapies (expressed as LEDD/Kg) and the developing or worsening of a preexisting PNP, correlate with the nutritional state. These data confirm the association between late-stage PD and malnutrition [20]. Of relevance, six of our patients successfully used the PEG-J tube to supplement their daily food intake with nocturnal enteral feeding. Additionally, in spite of the symptomatic LCIG effect on off-time reduction, our data indicate that this device-aided treatment seems to have no beneficial effect on the underlying neurodegenerative disease effect of PD, at least regarding two possible markers of disease progression such as WL and malnutrition. However, this speculation should be confirmed by a case-control study. Finally, an effect of LCIG on the intestinal flora and production of gut hormones affecting hunger cannot be excluded. Small intestinal bacterial overgrowth (SIBO) have been reported to be more common among PD patients if compared to controls [21]. SIBO has been associated to a severe pattern of PD symptoms, motor complications and axial disability, as well as to a possible malabsorption of dopaminergic medications [22]. While the interaction between LCIG and SIBO has not been investigated yet, specific studies seem required when considering the possible susceptibility to changes in the microbiota composition of patients receiving a therapy delivered through a feeding tube and the high frequency of gastrointestinal symptoms observed in association with LCIG.

In sum, our data highlight the importance of devoting specific attention, as well as periodic nutritional assessments in patients undergoing LCIG. The assessment of PD patients developing WL should include the evaluation of different possible causes, not only related to dyskinesias or motor complications, but also to dysphagia, cognitive impairment,

hallucinations, apathy, depression, and self-feeding difficulties, which should always be considered in advanced PD. The possibility of nocturnal enteral feeding should also be contemplated as an effective option in LCIG-treated PD patients, since a feeding tube is already available [23].

Several limitations should temper the strength of our conclusions, including the retrospective analysis of data collected as part of an open label observational study, and the lack of a control group treated with oral levodopa. Our main aim, however, was to investigate the prevalence and severity of WL in patients undergoing LCIG treatment rather than comparing LCIG and oral levodopa treatments.

### **Conclusions**

Weight loss may occur in over 60% of PD patients undergoing LCIG. Special attention is required in patients with dyskinesia, which might account for an increased energy expenditure. Clinicians should also consider that nutritional status of PD patients is independently related to indexes of disease progression such as motor symptoms severity and dysphagia. Periodic nutritional assessments seem required to identify patients that could benefit from additional enteral feeding. In addition, a reduction in the LCIG dose might be required to adjust for changes in the LEDD/kg ratio in patients developing WL.

**Funding:** The study had no specific funding.

## Full Financial Disclosures of all Authors

Dr. Margherita Fabbri, Laura Beccaria, Elisa Montanaro and Sara Palermo: no conflict of interest to report and no disclosures.

Dr. Zibetti Maurizio: no conflict of interest to report. Stock Ownership in medically-related fields: none; Honoraria to speak and grants: Medtronic, Zambon, UCB Pharma, and AbbVie; Advisory Boards: none; Partnership: none; Intellectual Property Rights: none; Expert Testimony: none; Employment: none; Contracts: none; Royalties: none; Other: none.

Dr. Alberto Romagnolo: no conflict of interest to report. Grant support and speaker honoraria from AbbVie, speaker honoraria from Chiesi Farmaceutici and travel grants from Lusofarmaco and UCB Pharma.

Dr. Aristide Merola: no conflict of interest to report. Stock Ownership in medically-related fields: none; Honoraria to speak: Medtronic, Abbott; Grants: NIH (KL2 TR001426), Cynapsus Therapeutics, Lundbeck, Abbott; Advisory Boards: Abbott, Abbvie; Partnership: none; Intellectual Property Rights: none; Expert Testimony: none; Employment: none; Contracts: none; Royalties: none; Other: none.

Prof. Joaquim J. Ferreira: no conflict of interest to report. Stock Ownership in medically-related fields: none; Consultancies: Ipsen, GlaxoSmithKline, Novartis, Teva, Lundbeck, Solvay, Abbott, BIAL, Merck-Serono and Merz; Advisory Boards: none; Partnership: none; Honoraria to speak: none; Grants: GlaxoSmithKline, Grunenthal, Teva and Fundação MSD; Intellectual Property Rights: none; Expert Testimony: none; Employment: none; Contracts: none; Royalties: none; Other: none.

Prof. Leonardo Lopiano: no conflict of interest to report. Stock Ownership in medically-related fields: none; Honoraria to speak and grants: Medtronic, Zambon, UCB Pharma, AbbVie and Doc Generici; Advisory Boards: none; Partnership: none; Intellectual Property

Rights: none; Expert Testimony: none; Employment: none; Contracts: none; Royalties: none;

Other: none.

## References

- [1]. Bachmann CG, Trenkwalder C. Body weight in patients with Parkinson's disease. *Mov Disord.* 2006 **21**: 1824-1830.
- [2]. Logrosino G, Sesso HD, Paffenbarger RS, Jr., Lee IM. Body mass index and risk of Parkinson's disease: a prospective cohort study. *Am J Epidemiol.* 2007 **166**: 1186-1190.
- [3]. Sharma JC, Lewis A. Weight in Parkinson's Disease: Phenotypical Significance. *Int Rev Neurobiol.* 2017 **134**: 891-919.
- [4]. Wills AM, Perez A, Wang J, *et al.* Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1. *JAMA Neurol.* 2016 **73**: 321-328.
- [5]. van der Burg JMM, Gardiner SL, Ludolph AC, Landwehrmeyer GB, Roos RAC, Aziz NA. Body weight is a robust predictor of clinical progression in Huntington disease. *Ann Neurol.* 2017 **82**: 479-483.
- [6]. Zibetti M, Merola A, Artusi CA, *et al.* Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience. *Eur J Neurol.* 2014 **21**: 312-318.
- [7]. Antonini A, Odin P, Opiano L, *et al.* Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care. *J Neural Transm.* 2013 **120**: 1553-1558.
- [8]. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *J Neurol Neurosurg Psychiatry.* 1992 **55**: 181-184.
- [9]. Kondrup J, Allison SP, Elia M, Vellas B, Plauth M. ESPEN guidelines for nutrition screening 2002. *Clin Nutr.* 2003 **22**: 415-421.

- Accepted Article
- [10]. Watson R, Bagnasco A, Catania G, Aleo G, Zanini M, Sasso L. The Edinburgh Feeding Evaluation in Dementia Scale: A Longitudinal Study in Nursing Home Residents. *Dement Geriatr Cogn Disord*. 2017 **44**: 196-202.
- [11]. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. *Mov Disord*. 2010 **25**: 2649-2653.
- [12]. Goetz CG, Stebbins GT, Tilley BC. Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores. *Mov Disord*. 2012 **27**: 1239-1242.
- [13]. J K. *Electrodiagnosis in Diseases of Nerve and Muscle: Principles and Practice*, 3rd edn. *Oxford University Press: New York, NY*. 2001.
- [14]. Barichella M, Cereda E, Cassani E, *et al*. Dietary habits and neurological features of Parkinson's disease patients: Implications for practice. *Clin Nutr*. 2017 **36**: 1054-1061.
- [15]. Antonini A, Poewe W, Chaudhuri KR, *et al*. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. *Parkinsonism Relat Disord*. 2017 **45**: 13-20.
- [16]. Sensi M, Cossu G, Mancini F, *et al*. Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. *Parkinsonism Relat Disord*. 2017 **38**: 90-92.
- [17]. Buongiorno M, Antonelli F, Camara A, *et al*. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry. *Parkinsonism Relat Disord*. 2015 **21**: 871-876.
- [18]. Barichella M, Cereda E, Pezzoli G. Major nutritional issues in the management of Parkinson's disease. *Mov Disord*. 2009 **24**: 1881-1892.
- [19]. Cardoso R, Miranda D, Ferreira JJ. Association Between Body Mass Index and Parkinson Disease. *JAMA Neurol*. 2016 **73**: 891-892.
- [20]. Tomic S, Pekic V, Popijac Z, *et al*. What increases the risk of malnutrition in Parkinson's disease? *J Neurol Sci*. 2017 **375**: 235-238.
- [21]. Hill-Burns EM, Debelius JW, Morton JT, *et al*. Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. *Mov Disord*. 2017 **32**: 739-749.
- [22]. Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. *Lancet Neurol*. 2015 **14**: 625-639.

- [23]. Bove F, Bentivoglio AR, Naranian T, Fasano A. Enteral feeding in Parkinson's patients receiving levodopa/carbidopa intestinal gel. *Parkinsonism Relat Disord.* 2017 **42**: 109-111.

## LEGEND FOR TABLES

**Table 1. Demographic, clinical and nutritional data of PD patients in treatment with LCIG.**

|                                     | <b>Baseline<br/>(n=44)</b>   | <b>Follow-up<br/>(n=44)</b>  | <b>P - value</b> |
|-------------------------------------|------------------------------|------------------------------|------------------|
| Age (yrs)                           | 67.4 ± 5.8                   | 71.7 ± 6.6                   | /                |
| Women (n/total (%))                 | 15/44 (34%)                  | /                            | /                |
| Age at disease onset (yrs)          | 53 ± 7.8                     | /                            | /                |
| Disease duration (yrs)              | 14 ± 5.8                     | 18.3 ± 6.5                   | <b>&lt;0.001</b> |
| Duodopa therapy duration (months)   | /                            | 51.6 ± 28.5                  | /                |
| LEDD                                | 1421 ± 335                   | 1533 ± 474                   | 0.069            |
| LEDD/Kg                             | 20.5 ± 6                     | 24.6 ± 8.4                   | <b>0.002</b>     |
| Clinical Phenotype n (%)            | AK= 34 (77%)<br>TD= 10 (23%) | /<br>/                       |                  |
| HY                                  | 3 ± 0.9                      | 3.3 ± 1.2                    | <b>0.003</b>     |
| Number per stage                    | 2= 18; 3=5;<br>4=21          | 2= 17; 3= 4; 4= 14;<br>5= 9; |                  |
| SE                                  | 63± 13                       | 56 ± 19                      | <b>&lt;0.001</b> |
| MDS.UPDRS II                        | 17.1 ± 7.2                   | 29.5 ± 9.6                   | <b>&lt;0.001</b> |
| MDS.UPDRS III                       | 31±12.4                      | 49.2 ± 15                    | <b>&lt;0.001</b> |
| UPDRS IV, Total score (items 32–42) | 9.5 ± 3.1                    | 6.1 ± 2.4                    | <b>&lt;0.001</b> |
| Dyskinesia duration (Item 32)       | 1.7 ± 1                      | 1.7 ± 0.8                    | 0.7              |
| Dyskinesia disability (Item 33)     | 1.2 ± 1.2                    | 1.2 ± 0.8                    | 0.9              |
| Off state duration (Item 39)        | 2 ± 0.6                      | 0.8 ± 0.5                    | <b>&lt;0.001</b> |
| MMSE                                | 27.2 ± 2.4                   | 24.1 ± 4 <sup>^</sup>        | <b>&lt;0.001</b> |
| BDI                                 | 14.5 ± 7.8                   | 18.5 ± 9.5 <sup>^</sup>      | <b>0.01</b>      |
| WL (kg) – n (%)                     | /                            | 7.6 ± 7.1 – 30 (68%)         | /                |
| % WL (ΔWL/weight at T0)             | /                            | 9.9 ± 10.5                   |                  |

|   |                |   |                  |
|---|----------------|---|------------------|
| WL $\geq$ 10kg, n (%)   | /              | 12 (27%)  |                  |
| BMI (Kg/m <sup>2</sup> )  | 26.1 $\pm$ 4.6 | 23.1 $\pm$ 4.1  | <b>&lt;0.001</b> |
| BMI < 22 kg/m <sup>2</sup> , n (%)                                      | 7 (16%)        | 19 (43%)  |                  |
| MNA total score   | NA             | 20.6 $\pm$ 4.5  | /                |
| MNA classification, n (%)   | NA             | Normal nutrition status: 16 (36%)<br>Undernutrition risk: 19 (43%)<br>Undernutrition state: 9 (21%) |                  |
| EdFED-Q   | /              | 2.3 $\pm$ 3.1   |                  |
| Excessive granulation tissue, n (%)                                     | /              | 18 (40%)  | /                |
| Device related complications (tube occlusion or stoma infection), n (%) |                | 17 (39%)  | /                |
| PNP (Total), n (%)  | 9 (20%)        | 17 (38%)  | <b>&lt;0.001</b> |
| Subclinical PNP, n (%)  | 8 (18%)        | 8 (18%)   |                  |
| Clinical PNP, n (%)   | 1 (2%)         | 9 (20%)   |                  |
| Nutrition consultancy, n (%)*   | 000            | 17 (38%)  | /                |
| Replacement therapy (Vitamin B12 and Folic acid)                        | 0              | 17 (38%)  | /                |
| Oral nutritional supplement, n (%)                                      |                | 9 (20%)   | /                |
| Enteral feeding, n (%)  |                | 6 (14%)   | /                |

Values are presented as mean  $\pm$  standard deviation (SD) if not otherwise specified. SE:

Schwab and England ADL Scale; HY: Hoehn Yahr Stage; LEDD: Levodopa equivalent daily

dose; MMSE: Mini Mental State Examination; BDI: Beck Depression Inventory Scale;

MNA: Mini nutritional assessment (total score <17 indicates undernutrition and 17-23.5

undernutrition risk, while over 24 is considered a normal nutritional status); BMI: body mass

index; EdFED-Q: Edinburgh Feeding Evaluation in Dementia Questionnaire; PNP: peripheral

polyneuropathy; (\*): at least one nutrition consultancy since LCIG treatment onset; (^): one

patient did not succeed in filling out the MMSE and BDI at T1 due to a severe dementia.



**Table 2. Univariate analysis and multiple linear regression analysis for weight loss and nutritional status**

|  | <b>Univariate analysis</b>                 |                  |
|--|--|------------------|
|  | <b>% of Weight loss*</b>                   |                  |
|  | <b>R</b>                                   | <b>P - value</b> |
| $\Delta$ LEDD/Kg                                 | 0.479                                      | 0.01             |
| LEDD/Kg  | 0.336                                      | 0.02             |
| UPDRS part IV                                    | 0.481                                      | 0.001            |
| “Dyskinesia duration”(item 32)                   | 0.563                                      | 0.001            |
| “Off-state duration” (item 39)                   | 0.40                                       | 0.007            |
| MNA score  | 0.408                                      | 0.006            |
|  | <b>Multiple linear regression analysis</b> |                  |
| <b>Co-variable</b>                               | <b><math>\beta</math></b>                  | <b>P - value</b> |
| “Dyskinesia duration” (item 32)                  | 0.408                                      | 0.033            |
|  | <b>Univariate analysis</b>                 |                  |
|  | <b>MNA score<sup>^^</sup></b>              |                  |
|  | <b>R</b>                                   | <b>P-value</b>   |
| HY   | 0.663                                      | <0.01            |
| SE   | 0.575                                      | <0.01            |
| MDS-UPDRS-III                                    | 0.527                                      | <0.001           |
| UPDRS-IV   | 0.4  | 0.07             |
| “off-state duration”(item 39)                    | -0.318                                     | 0.035            |
| Dysphagia severity (MDS-UPDRS item 2.3)          | -0.482                                     | 0.001            |
| Cognitive/mood profile (MDS-UPDRS items 1.1-1.5) | -0.419                                     | 0.005            |
| EdFED-Q  | -0.684                                     | <0.001           |
| MMSE   | 0.499                                      | <0.001           |
| LEDD/Kg  | -0.398                                     | 0.07             |
| $\Delta$ WL                                      | -0.315                                     | 0.015            |

| Co-variables                            | Multiple linear regression analysis |           |
|---|-------------------------------------|-----------|
|   | $\beta$                             | P - value |
| HY                                      | 0.308                               | 0.014     |
| Dysphagia severity (MDS-UPDRS item 2.3) | 0.236                               | 0.012     |
| MDS-UPDRS-III                           | 0.348                               | 0.015     |
| EdFED-Q                                 | 0.331                               | 0.017     |
| LEDD/Kg                                 | 0.309                               | 0.002     |

(\*) At the univariate analysis, no correlations were found with age, gender, clinical phenotype, disease duration, MMSE, BDI, LCIG treatment duration, dysphagia severity (MDS-UPDRS item 2.3), cognitive/mood profile (sum of the MDS-UPDRS items 1.1- 1.2- 1.3 -1.4-1.5), constipation severity (MDS. UPDRS item 1.11), “dyskinesia disability” (item 33), SE, HY, MDS-UPDRS-III,  $\Delta$ MDS-UPDRS-III, MMSE, the use of enteral feeding and the occurrence of device related complications. (^^) In addition, no correlations were found with age, gender, BDI, LCIG treatment duration, disease duration, dyskinesia duration and disability, the use of enteral feeding and the occurrence of device related complications at the univariate analysis. Significant variables have been reported for the results observed at the multivariate linear regression analysis.  $R^2$  of the model was 0,5 and 0,865 for WL percentage and MNA score, respectively.